Suchergebnisse - "Tantravahi, Srinivas K"

PubPharm (39)

1

Impact of academic medical center access on outcomes in multiple myeloma

enthalten in: American journal of hematology | 2023

von Vardell, V. | Ermann, D. | Tantravahi, S. | +5

2

Impact of academic medical center access on outcomes in multiple myeloma

enthalten in: American Journal of Hematology | 2023

von Vardell, V. | Ermann, D. | Tantravahi, S. | +5

3

Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia

enthalten in: British journal of haematology | 2022

von Tantravahi, S. | Huber, B. | Vagher, J. | +7

4

Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE) : a post-hoc analysis of molecular biomarkers in a phase 2 study

enthalten in: The Lancet. Haematology | 2022

von Pemmaraju, N. | Garcia, J. | Potluri, J. | +7

CommentIn: Lancet Haematol. 2022 Jun;9(6):e391-e392. - PMID 35576959

5

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response : Phase II Safety and Efficacy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Harrison, C. | Garcia, J. | Somervaille, T. | +16

CommentIn: J Clin Oncol. 2022 May 20;40(15):1693-1695. - PMID 35319999

6

A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm

enthalten in: Blood advances | 2022

von Li, P. | Venkatachalam, S. | Ospina Cordona, D. | +7

7

Genome‐wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia

enthalten in: British Journal of Haematology | 2022

von Tantravahi, S. | Huber, B. | Vagher, J. | +7

8

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2021

von Go, R. | Jacobsen, E. | Baiocchi, R. | +22

9

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

enthalten in: Leukemia | 2020

von Patel, A. | Pomicter, A. | Yan, D. | +9

10

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

enthalten in: Leukemia | 2020

von Atanackovic, D. | Yousef, S. | Shorter, C. | +10